Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial
dc.contributor.author | Garland, Anne | |
dc.date.accessioned | 2017-09-20T15:52:02Z | |
dc.date.available | 2017-09-20T15:52:02Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Hollinghurst, S., Carroll, F., Abel, A., Campbell, J., Garland, A., Jerrom, B., Kessler, D., Kuyken, W., Morrison, J., Ridgway, N., et al. (2014). Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial. The British Journal of Psychiatry, 204 (1), pp.69-76. | |
dc.identifier.other | 10.1192/bjp.bp.112.125286 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/8582 | |
dc.description.abstract | Background: Depression is expensive to treat, but providing ineffective treatment is more expensive. Such is the case for many patients who do not respond to antidepressant medication.; Aims: To assess the cost-effectiveness of cognitive-behavioural therapy (CBT) plus usual care for primary care patients with treatment-resistant depression compared with usual care alone.; Method: Economic evaluation at 12 months alongside a randomised controlled trial. Cost-effectiveness assessed using a cost-consequences framework comparing cost to the health and social care provider, patients and society, with a range of outcomes. Cost-utility analysis comparing health and social care costs with quality-adjusted life-years (QALYs).; Results: The mean cost of CBT per participant was £910. The difference in QALY gain between the groups was 0.057, equivalent to 21 days a year of good health. The incremental cost-effectiveness ratio was £14 911 (representing a 74% probability of the intervention being cost-effective at the National Institute of Health and Care Excellence threshold of £20 000 per QALY). Loss of earnings and productivity costs were substantial but there was no evidence of a difference between intervention and control groups.; Conclusions: The addition of CBT to usual care is cost-effective in patients who have not responded to antidepressants. Primary care physicians should therefore be encouraged to refer such individuals for CBT.; | |
dc.description.uri | https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/costeffectiveness-of-cognitivebehavioural-therapy-as-an-adjunct-to-pharmacotherapy-for-treatmentresistant-depression-in-primary-care-economic-evaluation-of-the-cobalt-trial/22971D29C7D672FB6D13AA2E7737CB58 | |
dc.subject | Drug therapy | |
dc.subject | Depressive disorder | |
dc.subject | Primary health care | |
dc.title | Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial | |
dc.type | Article |